A new paper by GeneraLife Italia has been published in the ‘Journal of Assisted Reproduction and Genetics’. The scientific study adds new evidence in favor of the DuoStim protocol, the double stimulation in a single ovarian cycle, with a focus on the cost-benefit ratio: “In this paper – comments Alberto Vaiarelli, first author and medical-scientific coordinator of the GeneraLife center in Rome – we have shown that the DuoStim can also be offered during the treatment: the outcome of the first ovarian stimulation is observed and, if this is below expectations, a second stimulation can be immediately carried out. The aim is clearly to obtain the largest possible number of embryos to be subjected to pre-implantation genetic diagnosis, to maximize the chances of identifying at least one chromosomally normal, thus increasing the possibility of pregnancy in a short period of time. By applying cost-effectiveness analysis methods, we found that, in patients of advanced maternal age and reduced ovarian reserve, the DuoStim is more efficient than the standard strategy, which instead contemplates a second stimulation only in the case of absence of pregnancy after first egg retrieval. In fact, almost all of the patients who do not get pregnant with this approach give up trying further, despite the fact that there are still tangible chances of success”.
